Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)

Luca Durelli(University of Turin), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), E. Verdun(University of Turin), Mauro Bergui(University of Turin), Angelo Ghezzi, Enrico Montanari(University of Ferrara), Elisabetta Versino(University of Turin), Pierangelo Barbero(Ospedale San Luigi Gonzaga)
The Lancet
April 1, 2002
Cited by 552


Related Papers